Consolidated Financial Results for Q2 FY2026 (IFRS)
Filed with TSE · · 20 pages · English
Earlier from GNI
- Notice Concerning the Completion of the Acquisition of All Shares of AYUMI Pharmaceutical Holdings KK (Conversion into a Wholly-Owned Subsidiary)
- Notice Regarding the Execution of a Loan Agreement Containing Financial Covenants
- Notice Concerning Filing of Form S-3 Registration Statement by Gyre Therapeutics
- GNI Group to Acquire Ayumi Pharmaceutical Holdings, Expanding Its Position as a Global Biopharmaceutical Company
- Transformational Acquisition of Ayumi Pharmaceutical Holdings
Later from GNI
- Q2 FY2026 Financial Results Corporate Presentation
- Notice Regarding Change in Major Shareholder
- Promotion of Proprietary Brand Business in the Medtech Segment
- From the Growth Market to TOPIX: GNI Group Newly Selected in the First Periodic Review Following TOPIX Reform
- Notice Regarding Third Quarter 2026 Financial Results and Update on the F351 NDA Review by Our Subsidiary Gyre Therapeutics
Follow GNI into a list and get an email when it puts out news.
Follow GNI